Abstract
Personalized medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It can improve health outcomes and healthcare sustainability by optimizing resource allocation. The European Union (EU) and China both prioritize PM. The IC2PerMed project aims to facilitate collaboration by developing a PM roadmap. This paper presents the main project’s output, a roadmap for implementing PM in the EU and China, promoting best practice exchange, and addressing potential barriers. We assessed PM in the EU and China by mapping policies, programs, funding mechanisms, and health ecosystems. Three Delphi surveys highlighted 65 priorities, which were synthesized into actions. The study identifies priorities to unlock PM's potential for healthcare transformation and better public health. The roadmap includes structural actions, like enhancing health literacy, fostering intersectoral and international collaboration, continuously reviewing technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Data interoperability and shared standards are critical for creating international platforms, and ethical, social, and regulatory considerations are universal in PM processes. A shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare.
Introduction: Bridging the Genomic Divide
Personalized Medicine (PM) represents a paradigm shift in healthcare, moving away from "one-size-fits-all" treatments toward interventions tailored to an individual’s genetic, clinical, and lifestyle profile. While the "genomic revolution" has been promised for decades, its global implementation remains hindered by significant fragmentation.
The European Union and China are global leaders in PM research, yet they operate within distinct regulatory frameworks—such as the EU’s General Data Protection Regulation (GDPR) versus China’s Data Security Law—and different healthcare ecosystems. Without a unified strategy, these regions risk creating "data islands" that stifle innovation and lead to redundant research efforts. The IC2PerMed project was established to bridge this gap, identifying common ground and building a collaborative roadmap to accelerate the clinical adoption of PM.
Methodology: Building Consensus Across Borders
The IC2PerMed roadmap was developed through a multi-phase, qualitative methodology designed to align international stakeholders:
- Mapping and Review: A comprehensive analysis of existing PM policies, funding mechanisms, and key actors in both the EU and China.
- Expert Engagement: A survey of 47 high-level experts to identify existing collaborations and areas of mutual interest.
- Workshops and Delphi Surveys: Nine workshops were conducted across three strategic pillars. These were followed by two rounds of Delphi surveys—a structured technique used to reach a reliable consensus among a panel of experts.
- Thematic Synthesis: Using NVivo software, the team synthesized 65 validated priorities into a final set of actionable roadmap items.
The IC2PerMed Roadmap
The core output of the project is a strategic framework organized into three pillars, each addressing a critical dimension of PM implementation.
Pillar I: Shaping Sustainable Healthcare
This pillar focuses on the societal and structural foundations of PM. Key priorities include enhancing health literacy among both patients and the healthcare workforce, addressing ethical, legal, and social implications (ELSI), and fostering public trust. Sustainability is viewed through the lens of resource optimization and the creation of resilient healthcare networks.
Pillar II: Innovation and Market
To move PM from the lab to the clinic, the roadmap highlights the need for new cost-effectiveness models. Traditional Health Technology Assessment (HTA) often struggles with the small patient cohorts typical of PM. The roadmap suggests integrating end-user perspectives and adopting international standards for data exchange to facilitate market entry and the adoption of Big Data and ICT solutions.
Pillar III: Research and Clinical Studies in PM
This pillar prioritizes "Omics" sciences (genomics, proteomics, etc.) and the translation of basic research into clinical practice. It calls for synergies between international funding agencies to support large-scale, cutting-edge projects that share both risk and data.
Key Strategic Insights
The roadmap reveals several critical areas where international alignment is essential:
- The Literacy Gap: PM adoption is as much a social challenge as a technical one. Education must ensure that the healthcare workforce is equipped to interpret and apply genomic data.
- Data Diplomacy: Bridging the gap between the EU’s consent-based data protection and China’s security-oriented framework requires "federated data infrastructures." These allow for cross-border analysis without the physical transfer of sensitive data.
- The Translational Gap: There remains a persistent mismatch between academic research and industrial application. The roadmap advocates for public-private collaboration frameworks that provide industry with better access to biological samples and standardized data.
Conclusion and Future Directions
The IC2PerMed roadmap provides a "doable" action plan for policymakers to synchronize PM development on a global scale. While cultural and political differences between the EU and China present challenges, the 65 validated priorities offer a clear path forward. Future efforts must focus on moving from strategic alignment to the actual implementation of bilateral standards, ensuring that the benefits of personalized medicine are accessible to populations in both regions and beyond.
Summary updated